drugset / Trial / NCT07472478
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
NaSequentialOpen-labelTreatment
Summary
This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.
Timeline
- Start
- 2026-03-15
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Garsorasib | Unknown | 600 mg | — |
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |